Updates of incretin-related drugs for the treatment of type 2 diabetes

Hirotaka Araki; Takeshi Matsumura; Noboru Furukawa; Eiichi Araki

doi:10.1111/jdi.13945

Updates of incretin-related drugs for the treatment of type 2 diabetes

J Diabetes Investig. 2023 Feb;14(2):189-192. doi: 10.1111/jdi.13945. Epub 2022 Nov 14.

Authors

Hirotaka Araki^{1

2}, Takeshi Matsumura¹, Noboru Furukawa^{1

3}, Eiichi Araki¹

Affiliations

¹ Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
² Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.
³ Center for Medical Education and Research, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Abstract

Mechanisms of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor dual-agonist in glycemic control and/or weight loss.

Keywords: Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists; Glucose-dependent insulinotropic polypeptide receptor.

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Dipeptidyl-Peptidase IV Inhibitors* / pharmacology
Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Incretins / pharmacology
Incretins / therapeutic use

Substances

Incretins
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor
Dipeptidyl-Peptidase IV Inhibitors